Cogent Biosciences(NASDAQ) COGT

Cogent Biosciences, Inc. makes drugs for rare genetic diseases. Its treatments help patients with serious blood and stomach disorders. These medicines fix specific cellular mistakes that drive illness.

Targeting Genetic Errors

• Bezuclastinib: Selective tyrosine kinase inhibitor designed to block the KIT D816V mutation in mast cell and stomach cancer patients.
• CGT4255: Mutant ErbB2 inhibitor targeting solid tumors that have spread to the brain.
• CGT6297: Selective inhibitor engineered to spare healthy cells while treating breast and other solid tumors.
• Research Programs: Preclinical efforts developing targeted inhibitors for KRAS and JAK2 genetic mutations.

Pathway to Market

• Filed three New Drug Applications with the FDA for bezuclastinib between Dec. 2025 and June 2026.
• Received Breakthrough Therapy Designation from the FDA for two separate patient populations in mast cell and stomach cancers.
• Achieved positive registrational trial results for all lead indications including gastrointestinal stromal tumors.
• Initiated expanded access programs in 2025 to allow patients to use experimental treatments before full regulatory approval.

What Makes Cogent Stand Out

The company utilizes a rational design approach to create therapies that target the molecular drivers of disease while minimizing effects on healthy tissue. Its internal research team operates specialized facilities in Colorado to discover new drug candidates for its growing pipeline.

Recent Financial Results

• Net loss reached $193.8 million for the six months ended June 30, 2026.
• Research and development spending grew to $146.2 million during the first half of 2026.
• General and administrative costs increased to $60.1 million in the six-month period ended June 30, 2026.
• Total cash, cash equivalents, and marketable securities were $792.3 million as of June 30, 2026.
• Available capital is expected to fund operations into late 2028 based on current cash and recent stock sales.

The Bottom Line

Cogent Biosciences is evolving from a clinical-stage researcher into a commercial organization as it prepares for potential drug launches. The company maintains a focus on precision medicine by developing a targeted portfolio of genetically defined therapies.